Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
3
60%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(2)

Detailed Status

Completed2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

completed240%
not_yet_recruiting120%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

NCT05569772
completedphase_3

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

NCT05890976
completedphase_2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

NCT05016882
not_yet_recruitingphase_3

Semaglutide Treatment in Type 1 Diabetes

NCT06909006
recruitingphase_2

COMMETS- Combination MCI Metabolic Syndrome

NCT06072963

Clinical Trials (5)

Showing 5 of 5 trials
NCT05569772Phase 3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Recruiting
NCT05890976Phase 3

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Completed
NCT05016882Phase 2

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Completed
NCT06909006Phase 3

Semaglutide Treatment in Type 1 Diabetes

Not Yet Recruiting
NCT06072963Phase 2

COMMETS- Combination MCI Metabolic Syndrome

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5